BCWorldPharm Co Ltd
KOSDAQ:200780
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BCWorldPharm Co Ltd
Total Equity
BCWorldPharm Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BCWorldPharm Co Ltd
KOSDAQ:200780
|
Total Equity
₩71.3B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
1%
|
|
|
Yuhan Corp
KRX:000100
|
Total Equity
₩2.3T
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Total Equity
₩813B
|
CAGR 3-Years
37%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Total Equity
₩1.2T
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Total Equity
₩267.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Total Equity
₩212.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
BCWorldPharm Co Ltd
Glance View
BCWORLD PHARM.Co., Ltd. engages in the manufacture and development of pharmaceutical products. The company is headquartered in Yeoju, Gyeonggi-Do. The company went IPO on 2014-12-15. The firm's products include anesthetic pain medication such as cancer pain treatment, muscle relaxants, anesthesia and pain relief drugs; circulation contracts such as hypertension and hyperlipidemia; antibiotics such as tuberculosis treatment; other prescription drugs such as peptic ulcer and osteoporosis. In addition, the Company develops improved drugs and new products.
See Also
What is BCWorldPharm Co Ltd's Total Equity?
Total Equity
71.3B
KRW
Based on the financial report for Dec 31, 2025, BCWorldPharm Co Ltd's Total Equity amounts to 71.3B KRW.
What is BCWorldPharm Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
1%
Over the last year, the Total Equity growth was -7%. The average annual Total Equity growth rates for BCWorldPharm Co Ltd have been -4% over the past three years , -7% over the past five years , and 1% over the past ten years .
